Merck Launches Your Hive of Whole Health for HIV Care
RAHWAY, N.J. — September 18, 2026 Merck announced the launch of Your Hive of Whole Health, a multi-year educational...
HIV
Advertisement
Gilead and PAHO Expand Lenacapavir HIV Prevention Access
FOSTER CITY, Calif. — September 17, 2026 Gilead Sciences, Inc. announced a new agreement with the Pan American Health...
FDA Approves Gilead’s Bixlenvo for HIV Treatment
Foster City, California, August 27, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Tolerance Bio Licenses Long-Acting IL-7 Therapy
Philadelphia, Pennsylvania, August 19, 2026 Tolerance Bio, Inc., a biotechnology company focused on preserving, regenerating, and modulating thymic function,...
GSK Invests £400M in Cambridge R&D Innovation Centre
LONDON, July 30, 2026 GSK has announced plans to establish a new global flagship research and development (R&D) centre...
Advertisements
GSK Accelerates R&D After Strong Q2 2026 Performance
LONDON, July 30, 2026 GSK has reported strong Q2 2026 financial results, driven by continued growth across its Specialty...
ViiV Healthcare Reports Positive Phase IIIb Dovato Results
London, July 27, 2026 ViiV Healthcare has announced positive Week 48 results from the Phase IIIb VOGUE study, demonstrating...
Merck & Co., Inc. Expands Global Access to Once-Monthly Alimatravir
RAHWAY, N.J., July 24, 2026 Merck has announced an ambitious global access strategy for alimatravir (MK-8527), its investigational once-monthly...
Gilead Sciences and Merck & Co. Deliver Positive ISLEND Phase 3 Results
FOSTER CITY, Calif. & RAHWAY, N.J., July 22, 2026 Gilead Sciences and Merck announced detailed results from the Phase...
Gilead Sciences Presents New HIV Prevention and Treatment Data at AIDS 2026
FOSTER CITY, Calif., July 22, 2026 Gilead Sciences announced an extensive scientific program for the 26th International AIDS Conference...
Advertisement
